RJA
EPIX

Raymond James & Associates’s ESSA Pharma EPIX Stock Holding History

Raymond James & Associates’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40,619
Closed -$74K – 3961
2022
Q3 		$74K Hold
40,619
– – ﹤0.01% 3658
2022
Q2 		$128K Hold
40,619
– – ﹤0.01% 3628
2022
Q1 		$251K Buy
+40,619
New +$357K ﹤0.01% 3533

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Raymond James & Associates's EPIX Position: Q4 2022 in Review

Raymond James & Associates sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 40,619 shares — an estimated $74K sold.

Raymond James & Associates first reported a position in EPIX in Q1 2022 and held it in 3 quarters. The position peaked at $251K in Q1 2022. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • Raymond James & Associates reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 40,619 ESSA Pharma shares in Q4 2022, an estimated $74K.
  • Raymond James & Associates first reported a position in ESSA Pharma in Q1 2022 and held it in 3 quarters.
  • Raymond James & Associates's ESSA Pharma position peaked at $251K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.